- Activity pressure is positive on the latest completed week.
BIG1
GER
Week ended 07 Aug 2026
Weekly Investor Report
Bio-Gate AG · Healthcare · Medical Instruments & Supplies
Latest close
2.90 EUR
-11.5%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -10.0% below the Trend Line and sits at 16.3% of its 52-week range. The latest completed week returned -11.5%, after a -5.7% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.
Setup score
23
out of 100
Latest Close
2.90 EUR
7 Aug 2026
1W Return
-11.5%
latest completed week
4W Return
-5.7%
short-term follow-through
12W Return
-27.0%
quarterly tape
Trend Breadth
17.3%
9 of 52 weeks active
Volume Ratio
0.9x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Next-week expectancy is negative at 44.40% based on similar historical setup states.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-11.5%
Latest completed week; four-week move -5.7%.
Indicator stack
10/65
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 44.40%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
50/100
5 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -10.0% below the Trend Line and sits at 16.3% of its 52-week range. The latest completed week returned -11.5%, after a -5.7% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1312-week average 0.19
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.13Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -5.7% over four weeks, -27.0% over 12 weeks, and -37.0% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year9
Trend breadth17.3%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.02Latest activity-pressure read.
Pressure change188.7%Four-week change in activity pressure.
Leadership-27.73Latest relative-leadership reading.
RS change-22.6%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Dec 2025
Field coverage 73%
Model confidence 58%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength64/100Blend of value, momentum, and quality. Underlying universe rank 37; rank 1 is best.
Value54/100Relative valuation strength. Underlying universe rank 47; rank 1 is best.
Quality54/100Profitability and accounting quality. Underlying universe rank 47; rank 1 is best.
Momentum55/100Medium-term price momentum. Underlying universe rank 46; rank 1 is best.
Growth55/100Revenue and earnings growth. Underlying universe rank 46; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 0.8x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -26.6% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 58.2% Gross profit retained from each unit of revenue.
- Operating margin
- -15.3% Operating profit retained from revenue.
- Free-cash-flow margin
- -19.1% Free cash flow generated from revenue.
- Return on invested capital
- -96.1% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 4.9% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -17.4% Net share repurchases relative to market value.
- Shareholder yield
- -17.4% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.7x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 5 relevant articles.
0 positive · 5 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-41.4%Distance below the 52-week high.
13-week volatility8.5%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2612 weeks finished lower.
Best week+22.4%Week of 1 May.
Worst week-14.7%Week of 24 Jul.
Latest week-11.5%Week of 7 Aug.
Shape of recent returns
Strong gains6
Modest gains7
Flat weeks1
Modest losses3
Sharp losses9
Recent vol8.5%13-week weekly-return volatility.
Base vol7.4%52-week weekly-return volatility.
Up/down split23/26Count of positive and negative weeks in the 52-week window.
Average skew5.6% / -6.2%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank64 / 78
Group average1.4%
Trend breadth39.7%
Trend39.7%active weekly trend signals
MD69.2%positive activity pressure
RS34.6%positive relative leadership
Four-week leaders
IndustryDE Medical Instruments & Supplies
4-week rank9 / 12
Group average0.3%
Trend breadth25.0%
Trend25.0%active weekly trend signals
MD75.0%positive activity pressure
RS8.3%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape24/100
Trend, activity pressure, participation, and risk combine to a 24/100 tape read.
Indicator analysis28/100Latest 12-week confirmation: trend 0/12, activity pressure 10/12, relative leadership 0/12.
Activity pressure 0.13; No reversal markers Next-Week ExpectancyNegative 44.40%Next-week expectancy is negative with a 44.40% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors56/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 99 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 5 relevant articles.
Bio-Gate AG: Karl Richter, Granting of 931,201 subscription rights as part of a rights offering. Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 2.90 EUR | -11.5% | 3.22 EUR | 4.31 EUR | 0.02 | -27.73 | 2.6K | Off |
| 31 Jul 2026 | 3.27 EUR | 12.9% | 3.27 EUR | 4.33 EUR | 0.14 | -17.03 | 7.9K | Off |
| 24 Jul 2026 | 2.90 EUR | -14.7% | 3.29 EUR | 4.35 EUR | 0.01 | -25.59 | 7.3K | Off |
| 17 Jul 2026 | 3.40 EUR | 10.6% | 3.33 EUR | 4.38 EUR | -0.02 | -12.82 | 2.1K | Off |
| 10 Jul 2026 | 3.08 EUR | 3.4% | 3.35 EUR | 4.40 EUR | -0.02 | -22.61 | 4.7K | Off |
| 3 Jul 2026 | 2.98 EUR | 0.8% | 3.38 EUR | 4.43 EUR | 0.00 | -27.96 | 1.4K | Off |
| 26 Jun 2026 | 2.95 EUR | -6.3% | 3.44 EUR | 4.46 EUR | 0.15 | -26.05 | 527 | Off |
| 19 Jun 2026 | 3.15 EUR | 1.6% | 3.50 EUR | 4.49 EUR | 0.29 | -22.79 | 816 | Off |
| 12 Jun 2026 | 3.10 EUR | -8.1% | 3.54 EUR | 4.53 EUR | 0.43 | -23.72 | 1.8K | Off |
| 5 Jun 2026 | 3.38 EUR | 3.8% | 3.56 EUR | 4.56 EUR | 0.57 | -18.14 | 207 | Off |
| 29 May 2026 | 3.25 EUR | -12.8% | 3.58 EUR | 4.59 EUR | 0.65 | -22.97 | 1.2K | Off |
| 22 May 2026 | 3.73 EUR | -6.3% | 3.60 EUR | 4.62 EUR | 0.69 | -11.76 | 2.8K | Off |
| 15 May 2026 | 3.98 EUR | 3.2% | 3.62 EUR | 4.66 EUR | 0.50 | -2.49 | 4.2K | Off |
| 8 May 2026 | 3.85 EUR | 8.5% | 3.62 EUR | 4.68 EUR | 0.17 | -6.83 | 5.0K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.